GLYCOSTEM THERAPEUTICS
Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company focused on developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells to treat several types of cancer. NK-cells are the body’s first line of defence because of the innate ability of NK-cells to rapidly and accurately identify and destroy cells under stress, such as cancer or virally-infected cells. Glycostem’s lead product, oNKord® , is produced in a closed system in Glycostem’s ... state-of-theart production facility in The Netherlands, from which the product can be distributed globally. The platform technology includes ex vivo expansion of a high number of pure and highly activated NK-cells for clinical applications. oNKord® successfully concluded phase I clinical trial (elderly and fragile AML patients), providing solid safety data and strong indication of clinical activity, including response on MRD. Glycostem expects to obtain GMP certification by the end of 2018 and is planning to enter pivotal clinical trial in Q1 2019. Thanks to the six patent families, longstanding technical expertise and resources, as well as ‘Orphan Drug Designation’, Glycostem has secured a leadership position in the global NK-cell market.
GLYCOSTEM THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2007-01-01
Address:
Oss, Noord-Brabant, The Netherlands
Country:
The Netherlands
Website Url:
http://www.glycostem.com
Total Employee:
11+
Status:
Active
Contact:
+31 (0) 412 211 001
Email Addresses:
[email protected]
Technology used in webpage:
Google Maps ReCAPTCHA V2 3 To 9 CcTLD Redirects
Current Employees Featured
Founder
Official Site Inspections
http://www.glycostem.com Semrush global rank: 6.83 M Semrush visits lastest month: 755
- Host name: vip.reactonline.nl
- IP address: 87.233.157.142
- Location: Netherlands
- Latitude: 52.3824
- Longitude: 4.8995
- Timezone: Europe/Amsterdam
More informations about "Glycostem Therapeutics" on Search Engine
Home page | glycostem
1 st Aug 2022 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, and medac GmbH, an international pharmaceutical company based in Germany, will partner to commercialize Glycostem’s lead product, oNKord ®.See details»
Investor | glycostem
Our organization is guided by a highly experienced Management Team and Board of Directors and supported by a Scientific Advisory Board that includes renowned experts in the field of innovative cancer therapeutics. Moreover, Glycostem is supported by a strong scientific network of academic and pharmaceutical partnerships.See details»
Glycostem Therapeutics | LinkedIn
Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for industrial...See details»
Taking cellular immunotherapy to the next level - glycostem
May 2021. Pioneering, developing and manufacturing. Glycostem is focused on the development of first-, second- and third-generation stem cell-derived Natural Killer cells (NK cells) as a therapeutic asset in the fight against cancer.See details»
Glycostem Therapeutics - Crunchbase Company Profile & Funding
Glycostem is a clinical stage biotech company developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells. Oss, Noord-Brabant, The Netherlands. 11-50. Private. glycostem.com/ 253,534. Highlights. Contacts 23. Employee Profiles 7. Similar Companies 3. Company Insights. Powered by AI.See details»
Glycostem announces new data presentation at EHA 2022 …
OSS, Netherlands, May 13, 2022 /PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer...See details»
Natural killer cells making better cancer immunotherapies
Glycostem Therapeutics is at the forefront of efforts to develop safer, more affordable cell therapies which are available off-the-shelf. Instead of working with T cells, Glycostem is...See details»
Natural killer cells making better cancer immunotherapies
By harvesting stem cells from umbilical cord blood and differentiating them into natural killer cells, Glycostem has developed oNKord, an affordable off-the-shelf cell therapy product...See details»
Glycostem launches pivotal oncology trial with evolved naked
Glycostem, a clinical-stage company, which in 2017 published a successful phase 1 trial with naked natural killer (NK) cells for acute myeloid leukemia (AML), is about to launch its first pivotal...See details»
Glycostem announces initial clinical data to be presented at 2021 …
OSS, Netherlands, Nov. 4, 2021 /PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer...See details»
Science and Technology | glycostem
Science and technology. Glycostem harvests the power of allogeneic Natural Killer (NK) cells. NK cells arise from blood forming stem cells and are an important part of the body's innate immune system. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing" properties, caused by a ...See details»
FDA grants Glycostem's oNKord® Orphan Drug Designation for Multiple Myeloma
OSS, The Netherlands, Oct. 12, 2020 /PRNewswire/ -- Glycostem Therapeutics, a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK) cells,...See details»
Zelluna Immunotherapy and Glycostem Therapeutics announce …
Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company, develops allogeneic cellular immunotherapy to treat several types of cancer. By harnessing the power of stem cell-derived Natural Killer (NK) cells, Glycostem’s products are a safe alternative to CAR-T-cells.See details»
glycostem
1st April, 2021 -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that Dr. Kai Pinkernell, M.D. joins Glycostem as Chief Medical Officer (CMO). Click here to open.See details»
Glycostem Therapeutics B.V. - BIO International Convention | BIO
Glycostem is focused on the development of first and second generation stem cell-derived Natural Killer cells (NK cells) as a therapeutic asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells.See details»
Glycostem Therapeutics - Contacts, Employees, Board Members, …
Organization. Glycostem Therapeutics. Connect to CRM. Summary People Technology Signals & News Similar Companies. Highlights. Employee Profiles 7. Contacts 23. About. Glycostem Therapeutics has 7 current employee profiles, including Chief Executive Officer Troels Jordansen. Contacts. 1 email found. View. 1 email found 2 phone numbers found. …See details»
Glycostem Therapeutics - Crunchbase
Glycostem is a clinical stage biotech company developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells.See details»
Glycostem initiates phase I/IIa (pivotal) trial to evaluate the safety ...
OSS, Netherlands, Nov. 20, 2020 /PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK)...See details»
Glycostem announces treatment of first patient in pivotal phase …
Dec 15, 2020 Netherlands -based Glycostem Therapeutics BV, a clinical stage biotech company, develops allogeneic cellular immunotherapy to treat several types of cancer. By harnessing the power of stem...See details»
Clinical trials | glycostem
Glycostem initiated a phase I/IIa (pivotal) trial to evaluate the safety and efficacy of oNKord ® in patients with Acute Myeloid Leukemia (AML) in November 2020. The WiNK trial will enrol 33 AML patients at eight clinical sites based in five European countries. Therapy. Indication. Trial name. oNKord®.See details»